Skip to main content

Dr. Robert W. Hagar, M.D.

Internal Medicine (Internal Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
43
In the NPI registry since
2007
Medicare patients seen, 2024
38

Licensed in California since 1984, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1983Medical school: University of Virginia School of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Internal Medicine Physician primary
    CA license G53126 (first issued 1984; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Internal Medicine per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
38
Services billed
310
Patients’ average age
47
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes13330
Established patient office or other outpatient visit, 40-54 minutes1813

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 14 payments worth $12,848 in total to this clinician.

By company
Vertex Pharmaceuticals Incorporated$12,347
Chiesi USA, Inc.$160
Agios Pharmaceuticals, Inc.$141
Novo Nordisk Inc$125
Pfizer Inc.$76.49
By type
Consulting Fee$10,983
Travel and Lodging$1,282
Food and Beverage$584

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 6, 2025Vertex Pharmaceuticals Incorporated
Aug 6, 2025
Consulting Fee$10,983
Jul 27, 2025Vertex Pharmaceuticals Incorporated
Jul 27, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$765
Jul 28, 2025Vertex Pharmaceuticals Incorporated
Jul 28, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$348
Jul 28, 2025Vertex Pharmaceuticals Incorporated
Jul 28, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$93.75
Jul 28, 2025Vertex Pharmaceuticals Incorporated
Jul 28, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$75.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $38,170 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
    Agios Pharmaceuticals, Inc.
  • A randomized doubleblind placebocontrolled multicenter study to assess the safety and efficacy of inclacumab in participants with sickle cell disease experiencing vasoocclusive crises
    Global Blood Therapeutics, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Oakland

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 8, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1760549182. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.